Corporate Mission

We dedicate ourselves to serving patients by leveraging our knowledge in science and biotechnology in order to provide society with valuable products which help people to live longer, happier and healthier lives.

Our near term growth strategy is to:

Develop niche markets by inventing and producing new or improved dosage forms of existing products.
Establish new sales channels and expand current marketing network to drive product market share.

Our Long term growth strategy is to:

Develop high margin biotech products (e.g aFGF) to sustain our long-term growth.
Increase focus in medicines for hyperglycemia, hypertension and hyperlipidemia, as well as market new generations of Chinese medicines in China and overseas.

We are able to compete in the highly fragmented pharmaceutical industry through our large manufacturing scale with cost controls and strong sales network. Our experienced management team, market insights and strong research and development (^R & D ̄) capabilities, enable us to develop and launch new and improved generic products based on market demand. We are also able to provide our therapeutics in a variety of delivery mechanisms such as tablets, capsules, troches, oral fluids, injections, frozen powder, germfree powder, and granules.



skonline 2006